MCID: INT068
MIFTS: 62

Intestinal Disease

Categories: Fetal diseases, Gastrointestinal diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Intestinal Disease

Summaries for Intestinal Disease

Disease Ontology : 12 A gastrointestinal system disease that is located in the intestine.

MalaCards based summary : Intestinal Disease, also known as intestinal diseases, is related to colitis and ulcerative colitis, and has symptoms including constipation, diarrhea and signs and symptoms, digestive. An important gene associated with Intestinal Disease is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Human T-cell leukemia virus 1 infection and Toll Comparative Pathway. The drugs Iron and Oxycodone have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and testes, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Wikipedia : 77 The gastrointestinal tract (digestive tract, digestional tract, GI tract, GIT, gut, or alimentary canal)... more...

Related Diseases for Intestinal Disease

Diseases in the Intestinal Disease family:

Chronic Intestinal Failure

Diseases related to Intestinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 166)
# Related Disease Score Top Affiliating Genes
1 colitis 30.6 MLH1 NOD2 TFF3 TNF UCN
2 ulcerative colitis 30.4 MLH1 NOD2 TNF UCN
3 adenocarcinoma 30.3 HRAS KRAS MLH1 TP53
4 colorectal adenocarcinoma 30.0 CEACAM5 HRAS KRAS MLH1 TP53
5 alpha-heavy chain disease 11.8
6 alpha chain disease 11.4
7 protozoal dysentery 11.3
8 crohn's disease 11.3
9 cystoisosporiasis 11.1
10 inflammatory bowel disease 11.1
11 sitosterolemia 10.7
12 bile acid synthesis defect, congenital, 1 10.7
13 diarrhea 5, with tufting enteropathy, congenital 10.7
14 inguinal hernia 10.7
15 umbilical hernia 10.7
16 short bowel syndrome 10.7
17 blind loop syndrome 10.7
18 cecal disease 10.7
19 diverticulitis 10.7
20 epilepsy occipital calcifications 10.7
21 granulomatous endometritis 10.6 CEACAM5 SDC1
22 type 1 diabetes mellitus 15 10.6 GCG HRAS
23 intracranial chondrosarcoma 10.6 CEACAM5 TP53
24 mature b-cell neoplasm 10.6 BCL6 SDC1 TP53
25 nasal cavity adenocarcinoma 10.6 HRAS KRAS TP53
26 liver angiosarcoma 10.6 HRAS KRAS TP53
27 ampulla of vater cancer 10.6 HRAS KRAS TP53
28 atrophic gastritis 10.6 GHRL TNF TP53
29 prostate squamous cell carcinoma 10.6 CEACAM5 HRAS TP53
30 sigmoid neoplasm 10.6 CEACAM5 HRAS KRAS
31 mixed cell type cancer 10.6 CEACAM5 HRAS TP53
32 rare adenocarcinoma of the breast 10.6 KRAS TP53
33 lung benign neoplasm 10.6 HRAS KRAS TP53
34 apocrine adenoma 10.6 CEACAM5 HRAS KRAS
35 aggressive digital papillary adenocarcinoma 10.6 CEACAM5 HRAS KRAS
36 gastroesophageal reflux 10.6 GCG GHRL TP53
37 ovarian cancer 1 10.6 CEACAM5 KRAS TP53
38 leukocyte disease 10.6 BCL6 SDC1 TNF TP53
39 malignant spiradenoma 10.6 CEACAM5 TP53
40 carcinosarcoma 10.6 HRAS KRAS TP53
41 cecum adenocarcinoma 10.6 HRAS KRAS MLH1
42 exanthem 10.6 HRAS KRAS TNF
43 leukemia, chronic lymphocytic 2 10.6 HRAS KRAS TP53
44 lichen planus 10.6 DEFB4A TNF TP53
45 cystadenocarcinoma 10.6 CEACAM5 HRAS TP53
46 overnutrition 10.6 GCG GHRL TNF
47 biliary papillomatosis 10.6 CEACAM5 HRAS KRAS TP53
48 ovary adenocarcinoma 10.5 CEACAM5 HRAS KRAS TP53
49 stomach disease 10.5 CEACAM5 GHRL MLH1 TP53
50 small intestine cancer 10.5 HRAS KRAS MLH1

Comorbidity relations with Intestinal Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Esophagitis
Heart Disease Intestinal Obstruction
Ischemic Heart Disease Paralytic Ileus

Graphical network of the top 20 diseases related to Intestinal Disease:



Diseases related to Intestinal Disease

Symptoms & Phenotypes for Intestinal Disease

UMLS symptoms related to Intestinal Disease:


constipation, diarrhea, signs and symptoms, digestive, anal or rectal pain

MGI Mouse Phenotypes related to Intestinal Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.92 GHRL HRAS KRAS MLH1 NOD2 TFF3
2 endocrine/exocrine gland MP:0005379 9.91 BCL6 CORT GHRL HRAS KRAS MLH1
3 homeostasis/metabolism MP:0005376 9.83 BCL6 CCR6 CORT F5 GHRL HPS4
4 hematopoietic system MP:0005397 9.81 BCL6 CCR6 HPS4 KRAS MLH1 NOD2
5 integument MP:0010771 9.23 F5 HPS4 HRAS KRAS MLH1 SDC1

Drugs & Therapeutics for Intestinal Disease

Drugs for Intestinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1375)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved, Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7439-89-6, 15438-31-0 27284 23925
2
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 76-42-6 5284603
3
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 465-65-6 5284596
4
Copper Approved, Investigational Phase 4,Not Applicable 7440-50-8 27099
5
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
6
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
7
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6 32051
8
Infliximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 170277-31-3
9
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302-25-0
10
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
11
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2921-57-5
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
13
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
14
Prucalopride Approved Phase 4,Phase 3,Phase 2 179474-81-8
15
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 428863-50-7
16
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81103-11-9 84029
17
Clofazimine Approved, Investigational Phase 4,Phase 3,Phase 2 2030-63-9 2794
18
Rifabutin Approved, Investigational Phase 4,Phase 3 72559-06-9 46783538 6323490
19
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
20
Ifosfamide Approved Phase 4,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
21
Etoposide Approved Phase 4,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
22
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
23
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
24
Epirubicin Approved Phase 4,Phase 2 56420-45-2 41867
25
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
27
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
28
Gemcitabine Approved Phase 4,Phase 3,Phase 1,Phase 2 95058-81-4 60750
29
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
30
Alvimopan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 156053-89-3 5488548
31
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
32
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
33
Diltiazem Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 42399-41-7 39186
34
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6 774
35
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
36
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
37
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
38
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 446-86-6 2265
39
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 103577-45-3 3883
40
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
41
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 138530-94-6, 103577-45-3 9578005
42
Ceftriaxone Approved Phase 4,Phase 2,Not Applicable 73384-59-5 5479530 5361919
43
Trimebutine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 39133-31-8
44
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 117976-89-3 5029
45
Hydromorphone Approved, Illicit Phase 4,Phase 3,Not Applicable 466-99-9 5284570
46
Methadone Approved, Illicit Phase 4 76-99-3 4095
47
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
48
Gabapentin Approved, Investigational Phase 4,Not Applicable 60142-96-3 3446
49
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
50
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 38396-39-3, 2180-92-9 2474

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
2 Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section Unknown status NCT02571881 Phase 4 Oxycodone;oxycodone-naloxone
3 Single-Operator Versus Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders Unknown status NCT01184690 Phase 4
4 Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass Unknown status NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
5 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
6 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
7 Vitamin D Substitution During Winter Time Unknown status NCT02958501 Phase 4 Colecalciferol
8 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
9 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
10 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
11 Double- Versus Single-balloon Enteroscopy for Obscure Small-bowel Bleeding Unknown status NCT01176864 Phase 4
12 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
13 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
14 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder Unknown status NCT02949232 Phase 4 Prednisolone;Placebo Oral Tablet
15 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
16 Prucalopride Prior to Small Bowel Capsule Endoscopy Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
17 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
18 Does Clinical Response Correlate With Serum Certolizumab Levels? Unknown status NCT02597829 Phase 4 Certolizumab Pegol
19 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
20 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
21 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
22 Lactobacillus Reuteri in Children With Constipation Unknown status NCT01388712 Phase 4
23 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
24 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
25 Alvimopan Use in Polytraumatized Patients Unknown status NCT03068975 Phase 4 Alvimopan;Placebo
26 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
27 Withholding Feeds During Red Blood Cell Transfusion and TRAGI Unknown status NCT02132819 Phase 4
28 Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
29 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission Unknown status NCT01817426 Phase 4 Infliximab
30 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
31 Optimizing Cimzia in Crohn's Patients Unknown status NCT01024647 Phase 4
32 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
33 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
34 VSL#3 Treatment in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
35 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
36 Pediatrics Anal Fissures Treatment With Polyethylene Glycol Unknown status NCT02419534 Phase 4 Polyethylene glycol;Polyethylene glycol with Diltiazem
37 Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
38 Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial Unknown status NCT01908465 Phase 4 Ebastine;Placebo
39 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
40 Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D Unknown status NCT01638208 Phase 4 VSL#3
41 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
42 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
43 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis Unknown status NCT02962245 Phase 4 berberine;regular treatment
44 Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis Unknown status NCT02579733 Phase 4 Azathioprine;Placebo
45 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
46 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
47 Oral vs Intravenous and Proton Pump Inhibitor (PPI)for Peptic Ulcer Bleeding (PUB) Unknown status NCT01123031 Phase 4 lansoprazole;esomeprazole
48 Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer Unknown status NCT00471029 Phase 4 esomeprazole
49 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
50 The Use of DPP-4 Inhibitors in Short Bowel Syndrome Unknown status NCT02653131 Phase 4 Dipeptidyl peptidase-4 inhibitor

Search NIH Clinical Center for Intestinal Disease

Cochrane evidence based reviews: intestinal diseases

Genetic Tests for Intestinal Disease

Anatomical Context for Intestinal Disease

MalaCards organs/tissues related to Intestinal Disease:

42
Colon, Liver, Testes, T Cells, Small Intestine, Lymph Node, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Intestinal Disease:

20
The Intestine

Publications for Intestinal Disease

Articles related to Intestinal Disease:

(show top 50) (show all 568)
# Title Authors Year
1
Clinical and endoscopic characteristics of sessile serrated adenomas/polyps with dysplasia/adenocarcinoma in a Korean population: A Korean Association for the Study of Intestinal Diseases (KASID) multicenter study. ( 30850671 )
2019
2
Differences in plasma and peritoneal fluid proteomes identifies potential biomarkers associated with survival following strangulating small intestinal disease. ( 30854696 )
2019
3
Oral Administration of Bovine Lactoferrin-Derived Lactoferricin (Lfcin) B Could Attenuate Enterohemorrhagic Escherichia coli O157:H7 Induced Intestinal Disease through Improving Intestinal Barrier Function and Microbiota. ( 30892034 )
2019
4
Complications of percutaneous endoscopic and radiologic gastrostomy tube insertion: a KASID (Korean Association for the Study of Intestinal Diseases) study. ( 30132209 )
2019
5
MicroRNA determines the fate of intestinal epithelial cell differentiation and regulates intestinal diseases. ( 30678626 )
2019
6
Norovirus strain types found within the second infectious intestinal diseases (IID2) study an analysis of norovirus circulating in the community. ( 30683063 )
2019
7
Risk factors associated with clinical outcomes of endoscopic mucosal resection for colorectal laterally spreading tumors: A Honam Association for the Study of Intestinal Diseases (HASID) multicenter study. ( 30945645 )
2019
8
Avian Influenza Virus Subtype H9N2 Affects Intestinal Microbiota, Barrier Structure Injury, and Inflammatory Intestinal Disease in the Chicken Ileum. ( 29783653 )
2018
9
Expression and location of IL-17A, E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease. ( 29548809 )
2018
10
Necroptosis in inflammatory bowel disease and other intestinal diseases. ( 30510938 )
2018
11
A Data-Based Hypothesis That Inflammatory Bowel Disease Unclassified (IBD-U) May Indicate That IBD Is a Spectrum of a Single Infectious Intestinal Disease. ( 30295733 )
2018
12
Socioeconomic status and infectious intestinal disease in the community: a longitudinal study (IID2 study). ( 29016791 )
2018
13
Mechanisms and function of autophagy in intestinal disease. ( 29130415 )
2018
14
Identifying free-text features to improve automated classification of structured histopathology reports for feline small intestinal disease. ( 29188759 )
2018
15
Surgical Management of Abomasal and Small Intestinal Disease. ( 29249602 )
2018
16
Toxic Causes of Intestinal Disease in Horses. ( 29397222 )
2018
17
Altered gut microbiota associated with intestinal disease in grass carp (Ctenopharyngodon idellus). ( 29777414 )
2018
18
Roles for selenium and selenoprotein P in the development, progression, and prevention of intestinal disease. ( 29778465 )
2018
19
Interactions of helminths with macrophages: therapeutic potential for inflammatory intestinal disease. ( 30113218 )
2018
20
Metastatic vulvovaginal Crohn disease in the setting of well-controlled intestinal disease. ( 30235375 )
2018
21
Gastric wall fat halo sign in patients without intestinal disease. ( 30521990 )
2018
22
Comparison of 2 differently sized endoscopic biopsy forceps in the evaluation of intestinal disease in cats. ( 30556184 )
2018
23
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases. ( 29593540 )
2018
24
The Interleukin-20 Cytokines in Intestinal Diseases. ( 29967613 )
2018
25
Skeletal muscle-gut axis: emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases. ( 30016852 )
2018
26
Pathomimetic modeling of human intestinal diseases and underlying host-gut microbiome interactions in a gut-on-a-chip. ( 30037458 )
2018
27
Mesenchymal stromal cell therapy in intestinal diseases. ( 30300331 )
2018
28
Immune-Mediated Mechanisms of Action of Probiotics and Synbiotics in Treating Pediatric Intestinal Diseases. ( 29303974 )
2018
29
Stool PCR for Gastrointestinal Pathogens in Patients With and Without Immune-Mediated Intestinal Diseases. ( 29411208 )
2018
30
Three-year colonoscopy surveillance after polypectomy in Korea: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter prospective study. ( 29422807 )
2018
31
Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases. ( 28670230 )
2017
32
Clinical outcome after enteroscopy for small bowel angioectasia bleeding: A Korean Associateion for the Study of Intestinal Disease (KASID) multiceter study. ( 27356264 )
2017
33
Intestinal Organoids: New Frontiers in the Study of Intestinal Disease and Physiology. ( 27632431 )
2017
34
Thromboembolism in Dogs with Protein-Losing Enteropathy with Non-Neoplastic Chronic Small Intestinal Disease. ( 27841681 )
2017
35
Do surveillance intervals in patients with more than five adenomas at index colonoscopy be shorter than those in patients with three to four adenomas? A Korean Association for the Study of Intestinal Disease study. ( 27862272 )
2017
36
Hsp65-Producing Lactococcus lactis Prevents Inflammatory Intestinal Disease in Mice by IL-10- and TLR2-Dependent Pathways. ( 28194152 )
2017
37
Recurrent diarrhoea in a renal transplant recipient: Early immunoproliferative small intestinal disease may be missed if not considered. ( 28205353 )
2017
38
Systematic review: exercise-induced gastrointestinal syndrome-implications for health and intestinal disease. ( 28589631 )
2017
39
Giardia co-infection promotes the secretion of antimicrobial peptides beta-defensin 2 and trefoil factor 3 and attenuates attaching and effacing bacteria-induced intestinal disease. ( 28622393 )
2017
40
Whole-Blood Taurine Concentrations in Cats With Intestinal Disease. ( 28626960 )
2017
41
Socioeconomic status is associated with symptom severity and sickness absence in people with infectious intestinal disease in the UK. ( 28645256 )
2017
42
An Ontology to Improve Transparency in Case Definition and Increase Case Finding of Infectious Intestinal Disease: Database Study in English General Practice. ( 28958989 )
2017
43
Comparing the clinical outcomes of young-onset and adult-onset ulcerative colitis: a multi-center Korean Association for the Study for Intestinal Diseases study. ( 27338135 )
2017
44
Risk of advanced colorectal neoplasm in patients with more than 10 adenomas on index colonoscopy: A Korean Association for the Study of Intestinal Diseases (KASID) study. ( 27785837 )
2017
45
Metabolomics as a Functional Tool in Screening Gastro Intestinal Diseases: Where are we in High Throughput Screening? ( 28000563 )
2017
46
Heavy rainfall and risk of infectious intestinal diseases in the most populous city in Vietnam. ( 28012659 )
2017
47
We are not alone: a case for the human microbiome in extra intestinal diseases. ( 28286571 )
2017
48
The Roles of Glutamine in the Intestine and Its Implication in Intestinal Diseases. ( 28498331 )
2017
49
Roles of amino acids in preventing and treating intestinal diseases: recent studies with pig models. ( 28616751 )
2017
50
AMP-activated protein kinase: a therapeutic target in intestinal diseases. ( 28835570 )
2017

Variations for Intestinal Disease

Copy number variations for Intestinal Disease from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 37762 1 94500000 107000000 Gain AMY1 Intestinal disease
2 37786 1 94700000 107200000 Loss AMY1 Intestinal disease
3 84156 14 23788159 23802256 Insertion TGM1 Intestinal disease

Expression for Intestinal Disease

Search GEO for disease gene expression data for Intestinal Disease.

Pathways for Intestinal Disease

GO Terms for Intestinal Disease

Cellular components related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 AOC1 CORT DEFB4A F5 GCG GHRL
2 extracellular region GO:0005576 9.36 AOC1 CEACAM5 CORT DEFB4A F5 GCG

Biological processes related to Intestinal Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.93 CORT GCG GHRL TNF UCN
2 positive regulation of gene expression GO:0010628 9.91 HRAS KRAS TNF TP53 UCN
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.86 GCG HRAS NOD2 TNF
4 negative regulation of apoptotic process GO:0043066 9.8 BCL6 CEACAM5 GCG GHRL TP53 UCN
5 positive regulation of protein phosphorylation GO:0001934 9.76 HRAS KRAS TNF UCN
6 positive regulation of JNK cascade GO:0046330 9.75 HRAS NOD2 TNF
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.74 GCG TNF UCN
8 regulation of inflammatory response GO:0050727 9.72 BCL6 NOD2 TNF
9 Ras protein signal transduction GO:0007265 9.7 HRAS KRAS TP53
10 positive regulation of interleukin-6 production GO:0032755 9.67 NOD2 TNF UCN
11 defense response GO:0006952 9.67 DEFB4A ICOSLG NOD2 TNF
12 maintenance of gastrointestinal epithelium GO:0030277 9.58 NOD2 TFF3
13 cytokine-mediated signaling pathway GO:0019221 9.55 BCL6 KRAS SDC1 TNF TP53
14 response to isolation stress GO:0035900 9.48 HRAS KRAS
15 positive regulation of corticotropin secretion GO:0051461 9.43 GHRL UCN
16 positive regulation of cortisol secretion GO:0051464 9.4 GHRL UCN
17 gastric emptying GO:0035483 9.26 GHRL UCN
18 response to glucocorticoid GO:0051384 9.26 KRAS SDC1 TNF UCN
19 positive regulation of MAP kinase activity GO:0043406 8.92 HRAS KRAS NOD2 TNF

Molecular functions related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 BCL6 CEACAM5 GCG ICOSLG SDC1 TNF
2 copper ion binding GO:0005507 9.33 AOC1 F5 TP53
3 hormone activity GO:0005179 8.92 CORT GCG GHRL UCN
4 protein binding GO:0005515 10.19 BCL6 CCR6 DEFB4A F5 GCG GHRL

Sources for Intestinal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....